SIGNDO Biotechnology is an innovative biotechnology company specializing in the R&D, as well as the industrialization of tumor-targeted fluorescent contrast agents and related products. Since SIGNDO Biotech founding in 2021, our team has been dedicating to providing doctors with tools required for tumor visualization. Goal of "Illuminate cancer, Precision surgery ", SIGNDO Biotech committed to help surgeons achieve a more complete surgical resection and help improve patient outcomes. Real-time Targeted Fluorescent Conjugate（RT
TFC
®）technology platform is a leading global technology platform, which can utilize small molecule fluorescence conjugate technology to build a multi-cancer product portfolio for intraoperative visualization of tumors by surgeons.
